California molecular diagnostics company CardioDx unveiled new details of its initial public offering, slated to raise $92 million through shares priced at $14-$16 apiece.

Once the IPO launches, CardioDx will trade on the Nasdaq stock market under the symbol "CDX."

The company has not yet set a launch date, but said it expects to offer about 5.8 million shares to the public and has laid out how it plans to use the funds.

CardioDx plans to use some of the funds to expand its commercial efforts, including its sales and marketing workforce; to fund operations as the company pursues more insurance coverage and reimbursement; to "conduct additional clinical and marketing activities" for the company’s Corus CAD blood-based gene expression test; to fund R&D activity; and for "general corporate purposes." CardioDx will later specify just the how much it plans to put toward each of those activities.